Integrated scFv identification and CAR T cell generation for AML targeting in vivo
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70146 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Yi Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, …. Hauptthemen laut MEDLINE: Single-Chain Antibodies, Leukemia, Myeloid, Acute, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Wilhelm-Sander-Stiftung, Deutsche José Carreras Leukämie-Stiftung.
Abstract (Originalsprache)
Cancer immunotherapy has witnessed remarkable advancements, particularly in the development of chimeric antigen receptor (CAR) T cell therapy. Here, we integrated single chain variable fragment (scFv) development with CAR T cell generation based on a newly developed scFv phagemid library. High‐throughput long‐read PacBio sequencing identified 4.5 × 10 7 unique full‐length scFv proteins within the generated library. As a proof of principle, we screened for scFvs targeting C‐type lectin‐like molecule‐1 (CLL1) with subsequent cloning into a third generation retroviral CAR backbone. Functional assays revealed the specificity and potency of these CAR T cells in targeting CLL1‐positive AML cells in vitro. In vivo studies reduced tumor burden and improved survival rates compared to controls. Taken together, screening for tumor‐specific scFvs against CLL1 can rapidly generate AML‐specific CAR T cells with effective tumor killing in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
- Molecular Medicine Partnership Unit (MMPU), European Molecular Biology Laboratory (EMBL) and Heidelberg University Hospital, Heidelberg, Germany.
- Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.
ORCID-Profile: Yi Liu, Chunan Liu, Michael Schmitt
Förderung
- Deutsche Forschungsgemeinschaft
- Wilhelm-Sander-Stiftung
- Deutsche José Carreras Leukämie-Stiftung
- Deutsche Krebshilfe
Zitieren
APA
Liu, Y., Lauk, A., Sedloev, D., Brysting, J., Cetin, E., Liu, C., Mönnig, M., Luft, T., Yun, H., Schmitt, M., Sauer, T., Zhou, F., Rohde, C., & Müller-Tidow, C. (2026). Integrated scFv identification and CAR T cell generation for AML targeting in vivo. International Journal of Cancer. https://doi.org/10.1002/ijc.70146
Vancouver
Liu Y, Lauk A, Sedloev D, Brysting J, Cetin E, Liu C, et al. Integrated scFv identification and CAR T cell generation for AML targeting in vivo. International Journal of Cancer. 2026. doi:10.1002/ijc.70146
BibTeX
@article{Liu2026,
author = {Liu, Yi and Lauk, Annika and Sedloev, David and Brysting, Josephine and Cetin, Ela and Liu, Chunan and Mönnig, Maximilian and Luft, Thomas and Yun, Haiyang and Schmitt, Michael and Sauer, Tim and Zhou, Fengbiao and Rohde, Christian and Müller-Tidow, Carsten},
title = {Integrated scFv identification and CAR T cell generation for AML targeting in vivo},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70146}
}
EUVIMED